col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer-Verlag: Reactions Weekly
  original article Date Title Authors   All Authors
1 [GO] 2021―Sep―17 Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination
2 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech
3 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium
4 [GO] 2021―Sep―17 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
5 [GO] 2021―Sep―12 Warnings of risks associated with ivermectin use for COVID-19
6 [GO] 2021―Sep―12 mRNA-based vs viral vector-based COVID-19 vaccines
7 [GO] 2021―Sep―12 Covid-19-vaccine-pfizer-biontech
8 [GO] 2021―Sep―12 COVID-19-Vaccine-Pfizer-BioNTech
9 [GO] 2021―Sep―12 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
10 [GO] 2021―Sep―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
11 [GO] 2021―Sep―04 Antihypertensives: sex differences in risk of COVID-19
12 [GO] 2021―Sep―04 Thrombocytopenia and thromboembolism after COVID-19 vaccination
13 [GO] 2021―Sep―04 COVID-19 Vaccine Pfizer BioNTech
14 [GO] 2021―Sep―04 AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
15 [GO] 2021―Sep―04 Covid-19-vaccine-Pfizer-BioNTech
16 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
17 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
18 [GO] 2021―Sep―04 Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab
19 [GO] 2021―Aug―27 Covid-19 vaccine pfizer biontech
20 [GO] 2021―Aug―27 Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
21 [GO] 2021―Aug―27 Janssen COVID-19 vaccine-related tinnitus and dizziness
22 [GO] 2021―Aug―27 Covid-19-vaccine-Pfizer-BioNTech
23 [GO] 2021―Aug―21 COVID-19 vaccination encouraged by the EMA/ECDC
24 [GO] 2021―Aug―21 Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada
25 [GO] 2021―Aug―21 Cerebral vein thrombosis after four COVID-19 vaccines in Europe
26 [GO] 2021―Aug―21 Covid-19-vaccine-pfizer-biontech
27 [GO] 2021―Aug―21 Covid-19-vaccine-Pfizer-BioNTech/prednisone
28 [GO] 2021―Aug―21 Remdesivir vs tocilizumab in COVID-19: adverse event profiles
29 [GO] 2021―Aug―13 NSAIDs do not increase risk or severity of COVID-19 infections
30 [GO] 2021―Aug―13 Cerebral venous sinus thrombosis after COVID-19 vaccination
31 [GO] 2021―Aug―13 Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
32 [GO] 2021―Aug―13 PRAC meeting 5 August 2021: COVID-19 vaccine safety issues
33 [GO] 2021―Aug―13 COVID-19-Vaccine-Pfizer-BioNTech
34 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech
35 [GO] 2021―Aug―13 Covid-19-Vaccine-Pfizer-Biontech
36 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech/levofloxacin
37 [GO] 2021―Aug―09 WHO GACVS reviews cases of GBS after COVID-19 vaccination
38 [GO] 2021―Aug―09 Rolling review of COVID-19 vaccine Vidprevtyn by EMA
39 [GO] 2021―Aug―09 Revisions of precautions for COVID-19 vaccines and other drugs in Japan
40 [GO] 2021―Aug―09 COVID-19-Vaccine-Pfizer-BioNTech
41 [GO] 2021―Aug―09 Covid-19-vaccine-pfizer-biontech
42 [GO] 2021―Aug―01 EMA assessing safety of anakinra in adults with COVID-19
43 [GO] 2021―Aug―01 PMDA: precautions should be revised for Covid-19 vaccine
44 [GO] 2021―Jul―23 Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome
45 [GO] 2021―Jul―23 PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines
46 [GO] 2021―Jul―23 COVID-19-Vaccine-Pfizer-BioNTech
47 [GO] 2021―Jul―23 Covid-19-vaccine-pfizer-biontech
48 [GO] 2021―Jul―17 AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
49 [GO] 2021―Jul―05 Myocarditis or pericarditis following COVID-19 vaccination
50 [GO] 2021―Jul―05 Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
51 [GO] 2021―Jul―05 COVID-19-vaccine-pfizer-biontech
52 [GO] 2021―Jul―05 Covid-19-vaccines
53 [GO] 2021―Jun―26 FDA reports recall of Innova COVID-19 antigen rapid qualitative test
54 [GO] 2021―Jun―26 Myocarditis and pericarditis after COVID-19 vaccination
55 [GO] 2021―Jun―26 PRAC June 2021 meeting highlights: COVID-19 vaccine AEs
56 [GO] 2021―Jun―26 US-labelled supply of Moderna's COVID-19 vaccine in Cananda
57 [GO] 2021―Jun―18 Biological or targeted synthetic DMARDs increase COVID-19 severity
58 [GO] 2021―Jun―18 Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents
59 [GO] 2021―Jun―18 Safeguarding against use of contaminated COVID-19 Vaccine Janssen
60 [GO] 2021―Jun―18 Heterogeneity in potential COVID-19 vaccine-related AEs
61 [GO] 2021―Jun―18 EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia
62 [GO] 2021―Jun―12 Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine
63 [GO] 2021―Jun―12 Many Danes with fever after COVID-19 vaccine would contact doctor
64 [GO] 2021―Jun―05 Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
65 [GO] 2021―Jun―05 Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
66 [GO] 2021―Jun―05 COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab
67 [GO] 2021―May―28 Bleeding and clotting with AstraZeneca's COVID-19 vaccine
68 [GO] 2021―May―28 Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca
69 [GO] 2021―May―21 COVID-19 vaccination during pregnancy: no increase in placental lesions
70 [GO] 2021―May―21 PRAC May 2021 meeting highlights: COVID-19 vaccine AEs
71 [GO] 2021―May―21 Do NSAIDs increase the severity of COVID-19?
72 [GO] 2021―May―14 COVID-19 vaccination errors in USA reported to ISMP
73 [GO] 2021―May―14 TTS with Janssen's COVID-19 vaccine
74 [GO] 2021―May―14 Anxiety disorders with Janssen's COVID-19 vaccine
75 [GO] 2021―May―14 AstraZeneca COVID-19 vaccine-related thromboembolism
76 [GO] 2021―May―14 AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
77 [GO] 2021―May―07 No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
78 [GO] 2021―May―07 FDA and CDC recommend resuming use of Janssen COVID-19 vaccine
79 [GO] 2021―May―07 COVID-19 vaccine adverse events reported via app
80 [GO] 2021―May―07 AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
81 [GO] 2021―May―07 New EMA/ECDC initiative for monitoring COVID-19 vaccines
82 [GO] 2021―May―03 PRAC: blood clots with Janssen's COVID-19 vaccine
83 [GO] 2021―May―03 Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
84 [GO] 2021―Apr―23 FDA remote evaluation of drug manufacturing during COVID-19
85 [GO] 2021―Apr―23 Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
86 [GO] 2021―Apr―23 Denmark ceases roll out of AstraZeneca's COVID-19 vaccine
87 [GO] 2021―Apr―23 COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets
88 [GO] 2021―Apr―23 PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines
89 [GO] 2021―Apr―23 Health Canada: AKI or ARF with remdesivir for COVID-19?
90 [GO] 2021―Apr―16 Should cancer patients receiving ICIs received COVID-19 vaccination?
91 [GO] 2021―Apr―16 Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand
92 [GO] 2021―Apr―16 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
93 [GO] 2021―Apr―10 Falsified COVID-19 vaccine recently identified in Mexico
94 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
95 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: no increased rate of VTE
96 [GO] 2021―Apr―02 No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
97 [GO] 2021―Apr―02 Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots
98 [GO] 2021―Apr―02 AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
99 [GO] 2021―Mar―26 Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
100 [GO] 2021―Mar―26 Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
101 [GO] 2021―Mar―26 Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
102 [GO] 2021―Mar―26 March 2021 PRAC meeting highlights include COVID-19 vaccine update
103 [GO] 2021―Mar―26 COVID-19-vaccine-Pfizer-BioNTech
104 [GO] 2021―Mar―19 COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
105 [GO] 2021―Mar―19 Reports of flu-like symptoms after COVID-19 vaccination
106 [GO] 2021―Mar―19 EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine
107 [GO] 2021―Mar―19 COVID-19 vaccine AE reports in Australia and New Zealand
108 [GO] 2021―Mar―13 Vial and carton labelling updated for Moderna COVID-19 vaccine
109 [GO] 2021―Mar―13 COVID-19 vaccine-related lymphadenopathy may affect breast screening
110 [GO] 2021―Feb―26 COVID-19 vaccine safety monitoring
111 [GO] 2021―Feb―19 Second HPRA safety update on COVID-19 vaccines
112 [GO] 2021―Feb―12 MHRA Yellow Card reports on COVID-19 vaccine adverse reactions
113 [GO] 2021―Feb―12 Safety update on COVID-19 vaccine Comirnaty finds no new concerns
114 [GO] 2021―Feb―05 Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
115 [GO] 2021―Feb―05 WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly
116 [GO] 2021―Feb―05 HPRA safety update on BioNTech and Moderna COVID-19 vaccines
117 [GO] 2021―Jan―29 Norway advised to assess the very frail prior to COVID-19 vaccination
118 [GO] 2021―Jan―29 Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses
119 [GO] 2021―Jan―29 ISMP reports: errors or hazards with COVID-19 vaccines
120 [GO] 2021―Jan―29 NSAID use does not increase risk of COVID-19-related death
121 [GO] 2021―Jan―22 Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination
122 [GO] 2021―Jan―22 Advice on COVID-19 vaccines approved in UK by MHRA
123 [GO] 2021―Jan―22 Safety of COVID-19 vaccines: who should see an allergist
124 [GO] 2021―Jan―21 Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
125 [GO] 2021―Jan―08 Pfizer COVID-19-related drug use and safety surveillance
126 [GO] 2021―Jan―06 Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
127 [GO] 2020―Dec―21 COVID-19-related deaths not increased with ACE inhibitor or ARB use
128 [GO] 2020―Dec―11 EMA and ICMRA urge continuation of COVID-19 vaccine safety trials
129 [GO] 2020―Nov―27 EMA's safety monitoring plan for COVID-19 vaccines
130 [GO] 2020―Nov―20 Drug-drug interactions in patients with COVID-19
131 [GO] 2020―Nov―13 EMA guidance on risk management plans for COVID-19 vaccines reviewed
132 [GO] 2020―Nov―06 Quality of ADR reporting evaluated for remdesivir trials of COVID-19
133 [GO] 2020―Nov―06 Hydroxychloroquine-related psychiatric disorders in COVID-19 patients
134 [GO] 2020―Nov―06 Phase III trial of Covid-19 treatment paused for safety concerns
135 [GO] 2020―Nov―06 Concerns raised with MHRA of anticoagulant use during pandemic
136 [GO] 2020―Oct―16 Remdesivir-related acute kidney injury in patients with COVID-19
137 [GO] 2020―Oct―02 Sex differences in ADR reports for drugs used to treat COVID-19
138 [GO] 2020―Aug―14 Proton pump inhibitors increase risk of COVID-19
139 [GO] 2020―Aug―14 Health Canada approves first drug for treatment of COVID-19
140 [GO] 2020―Jul―24 Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
141 [GO] 2020―Jul―17 Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
142 [GO] 2020―Jun―26 New potential interaction with emergency COVID-19 medicine remdesivir
143 [GO] 2020―Jun―12 Benefit-risk assessment for remdesivir in COVID-19
144 [GO] 2020―Jun―12 Risks of chloroquine or hydroxychloroquine use for COVID-19
145 [GO] 2020―Jun―05 COVID-19 pregnancy prevention guidance on teratogenic drugs
146 [GO] 2020―Jun―05 UK's MHRA publishes guidance for valproate PPP during pandemic
147 [GO] 2020―May―29 Chloroquine and hydroxychloroquine increase risk of death in COVID-19
148 [GO] 2020―May―29 Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
149 [GO] 2020―May―29 Cardiac adverse reactions with off-label Covid-19 treatments
150 [GO] 2020―May―23 US guidance issued for postmarketing AE reporting during pandemic
151 [GO] 2020―May―18 International Society of Pharmacovigilance: COVID-19 role
152 [GO] 2020―May―18 MHRA COVID-19 website for reporting ADRs and incidents
153 [GO] 2020―May―18 Risk of Covid-19 with renin-angiotensin-aldosterone system medications
154 [GO] 2020―May―11 Evaluation of potential therapies for COVID-19 global pandemic
155 [GO] 2020―May―11 Demand for potentially hazardous COVID-19 treatments
156 [GO] 2020―May―11 UMC: use appropriate COVID-19-related terms for ICSRs
157 [GO] 2020―May―04 ACEI inhibitors and ARBs do not increase severity of COVID-19
158 [GO] 2020―May―04 Safety concerns with higher dosage chloroquine in COVID-19 patients
159 [GO] 2020―May―04 High incidence of ADRs in COVID-19 patients in China
160 [GO] 2020―May―04 Antimalarial use in COVID-19 patients requires close monitoring
161 [GO] 2020―Apr―20 EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic
162 [GO] 2020―Apr―06 Regulatory agencies issue advice on use of NSAIDs for COVID-19


[de][en]

Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.009 sec